Protagonist: подана заявка в EMA на икотрокинру при бляшечном псориазе

Выдержка из источника

EX-99.1 2 tm2530353d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update Following the NDA submission for icotrokinra treatment of adults and adolescents with moderate to severe plaque psoriasis to the U.S. FDA in July, the European Medicines Agency (EMA) application was submitted in September Rusfertide granted breakthrough designation for patients in Polycythemia Vera (PV) and the subject of four presentations including 52-week results of the VERIFY Phase 3 Study at ASH, the 67 th Annual American Society of Hematology (ASH) meeting in December First patient dosed in the Phase 1 trial of PN-881, a first-in-class oral IL-17 peptide antagonist IND-enabling studies progressing as planned with triple-GLP/GIP/GCG ag

SEC 8-K

Ещё об этом активе

Решающее

18 мар. 2026 г.

11:49

JNJJohnson & Johnson

JNJ: FDA одобряет ICOTYDE (икотрокинра) при бляшечном псориазе средней и тяжёлой степени

Одобрение FDAПресс-релиз компанииОткрыть запись

Решающее

17 мар. 2026 г.

00:00

PTGXProtagonist

Protagonist Therapeutics, Inc · FDA одобряет Icotyde (icotrokinra)

Одобрение FDAСписок новых одобрений FDAОткрыть запись